Skip to content

Transepithelial Customized Cross-linking

Epithelium-on Customized Cross-linking for Keratoconus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04820608
Enrollment
50
Registered
2021-03-29
Start date
2018-02-01
Completion date
2022-01-01
Last updated
2021-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratoconus

Keywords

keratoconus, cross-linking, transepithelial, oxygen-boosted, customized, CXL

Brief summary

Customized remodeled vision (CuRV) is a new corneal cross-linking protocol for keratoconus, combining a transepithelial approach with customized energy application. Our aim is to follow-up our patients and establish the short-and long-term results of CuRV.

Detailed description

Customized remodeled vision is a protocol for oxygen-boosted, tranespithelial cross-linking, customized to apply higher energy at the apex of the cone, relatively lower to the cone area and none to healthy cornea. Thus CuRV promises to halt keratoconus progression, simultaneously offering potential for relatively good visual rehabilitation.Our primary outcomes involve spectacle-corrected distance visual acuity and changes in corneal topography/tomography and OCT parameters. These parameters include Kmax, thinnest corneal pachymetry, maximal anterior and posterior elevation, the Fourier analysis-derived irregularity index, and demarcation line depth.

Interventions

DEVICECross-linking

Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.

Sponsors

Ophthalmica Eye Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Topographic evidence of keratoconus: * maximum corneal curvature (Kmax) ≥47.00 D, * localized steepening on topographic maps, * localized elevation in the anterior and posterior corneal surfaces.

Exclusion criteria

* Hypersensitivity to riboflavin * Thinnest corneal pachymetry \< 380 μm * History of corneal surgery, including previous cross-linking * Corneal scarring * Aphakia * Pseudophakia * Any visually significant ocular condition

Design outcomes

Primary

MeasureTime frameDescription
Spectacle-corrected distance visual acuity1-3-6 months, 1 year, 2 yearsMeasurements will be performed on Early Treatment of Diabetic Retinopathy Study charts in logMAR units
Kmax1-3-6 months, 1 year, 2 yearsMaximal corneal keratometric value measured on Scheimpflung corneal tomography

Secondary

MeasureTime frameDescription
Maximal anterior & posterior elevation1-3-6 months, 1 year, 2 yearsValues as indicated on the Belin Ambrosio Enhanced Ectasia module of the Scheimpflung tomography device
Demarcation line depth1 monthMeasurements will be performed at 1st postoperative month, when the demarcation line is most visible, on anterior segment optical coherence tomography. The measurement will be performed manually on the scan approximating the thinnest corneal location with the device-native caliper set at 1:1μm.
Regularization index1-3-6 months, 1 year, 2 yearsRegularization index was proposed by Seiler et al. The measurement will be performed using the maximum flattening and steepening on the Comparison display of the Scheimpflung tomography device.
Fourier analysis-calculated maximum decentration1-3-6 months, 1 year, 2 yearsValues as indicated on the Fourier analysis module of the Scheimpflung tomography device
Thinnest corneal pachymetry1-3-6 months, 1 year, 2 yearsValues as indicated on Scheimpflung corneal tomography device

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026